Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology explains the role of CDK 4/6 inhibitors in advanced breast cancer and discusses whether they are interchangeable in treatment planning for patients.
The Role of CDK 4/6 Inhibitors in Advanced Breast Cancer
